Article ID Journal Published Year Pages File Type
5590769 Multiple Sclerosis and Related Disorders 2017 6 Pages PDF
Abstract
Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Genetics
Preview
Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab
Authors
, , , ,